The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Isis Pharmaceuticals changes its name to Ionis Pharmaceuticals

    Isis Pharmaceuticals, Inc. today announced that the company has changed its name to Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals is an original name that the Company has chosen to represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years. Ionis is focused on bringing its late-stage Phase 3 drugs, nusinersen (ISIS-SMNrx), volanesorsen and IONIS-TTRRx to the market and advancing its pipeline of high value drugs that have the potential to be first-in-class or best-in-class drugs to treat patients with life-threatening or serious diseases.

    “Our goal is to create medicines that will save patients’ lives, and we are proud to be at the forefront of creating innovative medicines,” said Lynne Parshall, chief operating officer at Ionis Pharmaceuticals. “We decided to change our company name because, when people see or hear our name, we want them to think about the life-saving medicines we are developing.”

    The company has a new website address: